11/7
08:36 am
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $18.00 price target on the stock.
Medium
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $18.00 price target on the stock.
11/7
06:20 am
arqt
Rating for ARQT
Medium
Report
Rating for ARQT
11/7
06:20 am
arqt
Rating for ARQT
Medium
Report
Rating for ARQT